UK-based device company Merxin has officially launched its new MRX006 multidose DPI, which has dual cavities and is designed specifically for triple therapies such as generic versions of Trelegy Ellipta. The company introduced the new DPI at DDL 2019 and reported that it fielded numerous inquiries about the device.
In 2019, the FDA indicated that Merxin’s MRX001 multidose blister DPI would be acceptable as an AB rated substitutable version of the Diskus DPI; the company’s goal is for the MRX003 to be an AB rated substitutable version of the Ellipta device.
Merxin Chief Business Officer Phillipe Rogueda commented, “MRX006 is a new milestone for Merxin. Ellipta is one the last blockbuster inhalation therapies not yet genericized, and we are capitalizing on our unparalleled experience in making devices to embark on the generic Ellipta journey. Our design aims to enable a generic 505j product to be filed before existing patents expire, carrying on with our mission to make the world healthier one breath at a time by making medicines cheaper and more accessible.”
